Hims & Hers Health: Still An Undervalued Company With Tremendous Upside (NYSE:HIMS)
· seekingalpha.com
Hims & Hers (HIMS) stock looks undervalued after a 578% run, with GLP-1 growth, rising subscribers, and $100+ 2030 upside—read the analysis and buy.
Raul Shah is the Chief Investment Officer of DocShah Financial LLC, a classic value investing firm. We manage investment portfolios and tax planning for clients...